40 research outputs found
Safra kesesinin intravasküler diffüz büyük hücreli lenfoması
Intravascular large B-cell lymphoma (IVLBCL) is a rare type of
extranodal B-cell lymphoma characterized by the growth of
lymphoma cells within the lumina of small vessels. Two major
patterns of clinical presentation have been recognized: the first
is in European countries, with brain and skin involvement, and
the second in Asian countries, where patients typically present
with multiorgan failure, hepatosplenomegaly, pancytopenia,
and hemophagocytic syndrome [1,2,3,4,5]. Primary IVLBCL of
the gallbladder is exceedingly rare
PD-L1 expression in immune cells is a favorable prognostic factor for nasopharyngeal carcinoma
Background: Programmed death-ligand 1 (PD-L1) has been determined as a reliable prognostic factor for various malignancies. In this study, we aimed to determine the prognostic effect of PD-L1 expression in tumor-infiltrating immune cells (TIICs) of nasopharyngeal carcinoma (NPC) patients.Methods: Seventy patients diagnosed with non-metastatic NPC were included in the study. PD-L1 expression on immune cells was analyzed by immunohistochemical method. Patients were categorized into two groups according to the PD-L1 expression level in TIICs (level of PD-L1 staining ≥5% positive vs <5% negative).Results: Median follow-up period was 34 months (range = 1 - 188). 1 and 2 years survival rate were found as 75% and 63% in PD-L1 negative TIICs group (47%), and 85% and 83% in PD-L1 positive TIICs group (53%), respectively. PD-L1 positivity in immune cells (ICs) was detected in 53% of the patients. The survival rate was found better in the PD- L1 positive group compared to the negative group (P = 0.049).Discussion: In conclusion, the survival rate was found significantly better in the PD-L1 positive TIICs group, compared to the negative group
Lipid peroxidation and antioxidant system in the blood of patients with Hodgkin's disease
Objectives: The purpose of this study was to measure the extent of lipid peroxidation and the status of antioxidants in patients with Hodgkin's disease